Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi & Shigeki Makino. (2018) Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Modern Rheumatology 28:2, pages 227-234.
Read now
Read now
Jörg Mahlich & Rosarin Sruamsiri. (2016) Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Preference and Adherence 10, pages 1509-1519.
Read now
Read now
Eri Sato, Eiichi Tanaka, Moeko Ochiai, Yoko Shimizu, Akiko Kobayashi, Kumi Shidara, Daisuke Hoshi, Naoki Sugimoto, Eisuke Inoue, Yohei Seto, Ayako Nakajima, Atsuo Taniguchi, Shigeki Momohara & Hisashi Yamanaka. (2015) Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Modern Rheumatology 25:3, pages 350-357.
Read now
Read now
Yoshiya Tanaka, Satoshi Kubo, Hisashi Yamanaka, Koichi Amano, Shintaro Hirata, Eiichi Tanaka, Hayato Nagasawa, Hidekata Yasuoka & Tsutomu Takeuchi. (2014) Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia® as Biological Intensive Treatment for RA (ORBIT) study. Modern Rheumatology 24:5, pages 754-762.
Read now
Read now
Shunsuke Fukuyo, Kazuyoshi Saito, Kunihiro Yamaoka, Norifumi Sawamukai, Shintaro Hirata, Masao Nawata, Shigeru Iwata & Yoshiya Tanaka. (2014) Efficacy and safety of reducing duration of infliximab infusion. Modern Rheumatology 24:2, pages 275-280.
Read now
Read now
Toshihisa Kojima, Yuichiro Yabe, Atsushi Kaneko, Yuji Hirano, Hisato Ishikawa, Masatoshi Hayashi, Hiroyuki Miyake, Hideki Takagi, Takefumi Kato, Kenya Terabe, Tsuyoshi Wanatabe, Hiroki Tsuchiya, Daihei Kida, Tomone Shioura, Koji Funahashi, Daizo Kato, Hiroyuki Matsubara, Nobunori Takahashi, Yosuke Hattori, Nobuyuki Asai & Naoki Ishiguro. (2013) Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Modern Rheumatology 23:5, pages 977-985.
Read now
Read now
Tsutomu Takeuchi, Yoshiya Tanaka, Yuko Kaneko, Eiichi Tanaka, Shintaro Hirata, Takahiko Kurasawa, Satoshi Kubo, Kazuyoshi Saito, Kumi Shidara, Noriko Kimura, Hayato Nagasawa, Hideto Kameda, Koichi Amano & Hisashi Yamanaka. (2012) Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Modern Rheumatology 22:3, pages 327-338.
Read now
Read now
Hiroki Wakabayashi, Masahiro Hasegawa, Yosuke Nishioka, Akihiro Sudo & Kusuki Nishioka. (2012) Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study. Modern Rheumatology 22:1, pages 116-121.
Read now
Read now
Shunsuke Mori & Yukitaka Ueki. (2011) Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab. Modern Rheumatology 21:6, pages 628-636.
Read now
Read now
Shin-ya Kawashiri, Atsushi Kawakami, Naoki Iwamoto, Keita Fujikawa, Toshiyuki Aramaki, Mami Tamai, Satoshi Yamasaki, Hideki Nakamura, Tomoki Origuchi, Yukitaka Ueki, Kiyoshi Migita, Akinari Mizokami, Kiyoshi Aoyagi & Katsumi Eguchi. (2011) In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Modern Rheumatology 21:4, pages 370-374.
Read now
Read now
Iris Goetz, Gebra Cuyún Carter, Melanie Lucero, Victoria Zarotsky, Carlos I. Alatorre, Ronald A. Cantrell, Rosirene Paczkowski & Kimberly L. Sterling. (2011) Review of treatment response in rheumatoid arthritis: assessment of heterogeneity. Current Medical Research and Opinion 27:4, pages 697-711.
Read now
Read now
Masahiro Tada, Takeshi Nakanishi, Chika Hirata, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani, Hiroaki Nakamura & Tatsuya Koike. (2010) Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis. Modern Rheumatology 20:6, pages 598-601.
Read now
Read now
Hideto Kameda, Yukitaka Ueki, Kazuyoshi Saito, Shouhei Nagaoka, Toshihiko Hidaka, Tatsuya Atsumi, Michishi Tsukano, Tsuyoshi Kasama, Shunichi Shiozawa, Yoshiya Tanaka & Tsutomu Takeuchi. (2010) Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Modern Rheumatology 20:6, pages 531-538.
Read now
Read now
Hayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, Koichi Amano & Tsutomu Takeuchi. (2010) Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. Modern Rheumatology 20:4, pages 337-342.
Read now
Read now
Toshiyuki Aramaki, Atsushi Kawakami, Naoki Iwamoto, Keita Fujikawa, Shin-ya Kawashiri, Mami Tamai, Kazuhiko Arima, Makoto Kamachi, Satoshi Yamasaki, Hideki Nakamura, Munetoshi Nakashima, Akinari Mizokami, Masako Furuyama, Naoki Matsuoka, Yukitaka Ueki, Hiroaki Ida, Tomoki Origuchi, Kiyoshi Aoyagi & Katsumi Eguchi. (2009) Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. Modern Rheumatology 19:6, pages 652-656.
Read now
Read now
Tsutomu Takeuchi, Nobuyuki Miyasaka, Kazuhiko Inoue, Tohru Abe & Takao Koike. (2009) Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Modern Rheumatology 19:5, pages 478-487.
Read now
Read now
Naoki Iwamoto, Atsushi Kawakami, Keita Fujikawa, Toshiyuki Aramaki, Shin-ya Kawashiri, Mami Tamai, Kazuhiko Arima, Kunihiro Ichinose, Makoto Kamachi, Satoshi Yamasaki, Hideki Nakamura, Munetoshi Nakashima, Akinari Mizokami, Akiko Goto, Takaaki Fukuda, Naoki Matsuoka, Yukitaka Ueki, Toshiaki Tsukada, Kiyoshi Migita, Fumiko Shoumura, Yojiro Kawabe, Kazutaka Shibatomi, Masanobu Mine, Hiroaki Ida, Tomoki Origuchi, Kiyoshi Aoyagi & Katsumi Eguchi. (2009) Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Modern Rheumatology 19:5, pages 488-492.
Read now
Read now
Hayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, Kouichi Amano & Tsutomu Takeuchi. (2009) Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. Modern Rheumatology 19:2, pages 166-172.
Read now
Read now
Tsutomu Takeuchi, Hisashi Yamanaka, Eisuke Inoue, Hayato Nagasawa, Masao Nawata, Katsunori Ikari, Kazuyoshi Saito, Naoya Sekiguchi, Eri Sato, Hideto Kameda, Shigeru Iwata, Takeshi Mochizuki, Kouichi Amano & Yoshiya Tanaka. (2008) Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Modern Rheumatology 18:5, pages 447-454.
Read now
Read now
Articles from other publishers (26)
Stanley Cohen, Jeffrey R. Curtis, Theodore Mellors, Lixia Zhang, Johanna B. Withers, Alex Jones, Susan D. Ghiassian & Viatcheslav R. Akmaev. (2022) Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis. Rheumatology and Therapy.
Crossref
Crossref
Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, Shiro Ohshima, Makoto Inoue, Yutaka Yoshioka & Hisashi Yamanaka. (2022) Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics. Modern Rheumatology 32:4, pages 718-727.
Crossref
Crossref
Pedro Santos-Moreno, Guillermo Sánchez & Carlos Castro. (2019) Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis. Medicine 98:5, pages e14181.
Crossref
Crossref
Enrique R Soriano, Analia Dellepiane, Gabriela Salvatierra, Cristian Alejandro Benítez, Rodrigo Garcia Salinas & Carlos Baruzzo. (2018) Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. Future Science OA 4:4, pages FSO289.
Crossref
Crossref
Shunsuke Mori, Tamami Yoshitama & Yukitaka Ueki. (2018) Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients. Internal Medicine 57:5, pages 663-670.
Crossref
Crossref
Hotaka Maruyama, Shinji Miyake & Tatsuo Kurokawa. (2016) Does Use of a Biosimilar Product Reduce the Expenditure of Patients?. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 42:7, pages 499-511.
Crossref
Crossref
C A Callaghan, A C Boyter, A B Mullen & E R McRorie. (2014) Biological therapy for rheumatoid arthritis: is personalised medicine possible?. European Journal of Hospital Pharmacy 21:4, pages 229-237.
Crossref
Crossref
Koshiro SONOMOTO, Kunihiro YAMAOKA & Yoshiya TANAKA. (2014) An Approach to Bone and Cartilage Repair of Rheumatoid Arthritis by Mesenchymal Stem Cells間葉系幹細胞による関節リウマチの骨軟骨再生へのアプローチ. Journal of UOEH 36:2, pages 141-146.
Crossref
Crossref
Kunihiko Umekita, Toshihiko Hidaka, Shunichi Miyauchi, Shiro Ueno, Kazuyoshi Kubo, Ichiro Takajo, Yayoi Hashiba, Yasufumi Kai, Yasuhiro Nagatomo & Akihiko Okayama. (2014) Treatment With Anti-Tumor Necrosis Factor Biologic Agents in Human T Lymphotropic Virus Type I-Positive Patients With Rheumatoid Arthritis. Arthritis Care & Research 66:5, pages 788-792.
Crossref
Crossref
Qianwen Lv, Yufeng Yin, Xin Li, Guangliang Shan, Xiangni Wu, Di Liang, Yongzhe Li & Xuan Zhang. (2014) The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis. PLoS ONE 9:2, pages e89442.
Crossref
Crossref
Eva Salgado, José Ramón Maneiro, Loreto Carmona & Juan Gómez-Reino. (2014) Facteur rhumatoïde et réponse aux anti-TNF dans la polyarthrite rhumatoïde : revue systématique et méta-analyse d’études observationnelles. Revue du Rhumatisme 81:1, pages 58-68.
Crossref
Crossref
Eva Salgado, José Ramón Maneiro, Loreto Carmona & Juan Gómez-Reino. (2014) Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: Systematic review and meta-analysis of observational studies. Joint Bone Spine 81:1, pages 41-50.
Crossref
Crossref
Nobunori Takahashi, Toshihisa Kojima, Atsushi Kaneko, Daihei Kida, Yuji Hirano, Takayoshi Fujibayashi, Yuichiro Yabe, Hideki Takagi, Takeshi Oguchi, Hiroyuki Miyake, Takefumi Kato, Naoki Fukaya, Hisato Ishikawa, Masatoshi Hayashi, Seiji Tsuboi, Yasuhide Kanayama, Daizo Kato, Koji Funahashi, Hiroyuki Matsubara, Yosuke Hattori, Masahiro Hanabayashi, Shinya Hirabara, Kenya Terabe, Yutaka Yoshioka & Naoki Ishiguro. (2013) Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clinical Rheumatology 33:1, pages 39-47.
Crossref
Crossref
Abdulla Al Masud Khan, Neil Alles, Niroshani S. Soysa, Md. Abdullah Al Mamun, Kenichi Nagano, Risako Mikami, Yuriko Furuya, Hisataka Yasuda, Keiichi Ohya & Kazuhiro Aoki. (2013) The local administration of TNF-α and RANKL antagonist peptide promotes BMP-2-induced bone formation. Journal of Oral Biosciences 55:1, pages 47-54.
Crossref
Crossref
Jinhyun KimHeejung RyuDae-Hyun YooSung-Hwan ParkGwan-Gyu SongWon Park, Chul-Soo ChoYeong-Wook Song. (2013) A Clinical Trial and Extension Study of Infliximab in Korean Patients with Active Rheumatoid Arthritis despite Methotrexate Treatment. Journal of Korean Medical Science 28:12, pages 1716.
Crossref
Crossref
Yoshiya Tanaka. (2012) Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Current Opinion in Rheumatology 24:3, pages 319-326.
Crossref
Crossref
Hiroyuki Nakachi, Kazuhiro Aoki, Nobuyoshi Tomomatsu, Neil Alles, Kenichi Nagano, Masashi Yamashiro, Hongtao Zhang, Ramachandran Murali, Mark I. Greene, Keiichi Ohya & Teruo Amagasa. (2012) A structural modulator of tumor necrosis factor type 1 receptor promotes bone formation under lipopolysaccharide-induced inflammation in a murine tooth extraction model. European Journal of Pharmacology 679:1-3, pages 132-138.
Crossref
Crossref
Yoshiya Tanaka. (2011) Paradigm Shift of Diagnosis and Treatment of Rheumatoid Arthritis.. Nihon Naika Gakkai Zasshi 100:7, pages 1978-1986.
Crossref
Crossref
Tsutomu Takeuchi & Hideto Kameda. (2010) The Japanese experience with biologic therapies for rheumatoid arthritis. Nature Reviews Rheumatology 6:11, pages 644-652.
Crossref
Crossref
Yoshiya Tanaka. (2010) Achieving drug-free remission: elucidating the role of TNF in rheumatoid arthritisinhibitors. International Journal of Clinical Rheumatology 5:4, pages 391-393.
Crossref
Crossref
Hayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, Koichi Amano & Tsutomu Takeuchi. (2010) Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. Modern Rheumatology 20:4, pages 337-342.
Crossref
Crossref
Toshiyuki Aramaki, Atsushi Kawakami, Naoki Iwamoto, Keita Fujikawa, Shin-ya Kawashiri, Mami Tamai, Kazuhiko Arima, Makoto Kamachi, Satoshi Yamasaki, Hideki Nakamura, Munetoshi Nakashima, Akinari Mizokami, Masako Furuyama, Naoki Matsuoka, Yukitaka Ueki, Hiroaki Ida, Tomoki Origuchi, Kiyoshi Aoyagi & Katsumi Eguchi. (2009) Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. Modern Rheumatology 19:6, pages 652-656.
Crossref
Crossref
Tsutomu Takeuchi, Nobuyuki Miyasaka, Kazuhiko Inoue, Tohru Abe & Takao Koike. (2009) Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Modern Rheumatology 19:5, pages 478-487.
Crossref
Crossref
Naoki Iwamoto, Atsushi Kawakami, Keita Fujikawa, Toshiyuki Aramaki, Shin-ya Kawashiri, Mami Tamai, Kazuhiko Arima, Kunihiro Ichinose, Makoto Kamachi, Satoshi Yamasaki, Hideki Nakamura, Munetoshi Nakashima, Akinari Mizokami, Akiko Goto, Takaaki Fukuda, Naoki Matsuoka, Yukitaka Ueki, Toshiaki Tsukada, Kiyoshi Migita, Fumiko Shoumura, Yojiro Kawabe, Kazutaka Shibatomi, Masanobu Mine, Hiroaki Ida, Tomoki Origuchi, Kiyoshi Aoyagi & Katsumi Eguchi. (2009) Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Modern Rheumatology 19:5, pages 488-492.
Crossref
Crossref
Hayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, Kouichi Amano & Tsutomu Takeuchi. (2008) Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. Modern Rheumatology 19:2, pages 166-172.
Crossref
Crossref
Tsutomu Takeuchi, Hisashi Yamanaka, Eisuke Inoue, Hayato Nagasawa, Masao Nawata, Katsunori Ikari, Kazuyoshi Saito, Naoya Sekiguchi, Eri Sato, Hideto Kameda, Shigeru Iwata, Takeshi Mochizuki, Kouichi Amano & Yoshiya Tanaka. (2008) Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Modern Rheumatology 18:5, pages 447-454.
Crossref
Crossref